Search results for: d842V

Home/Search: d842V
1 02, 2011

D842V Gets Its Moment in the Spotlight

By |2018-06-12T11:11:01-04:00February 1st, 2011|D842V, News, Patient Registry|

The Gleevec for GIST story continues to remain one of the most successful stories in oncology. What could be better than a drug that works in 85 percent of patients? As great as this story is, there is room for improvement. Half of the patients on Gleevec for metastatic disease will progress in the first two years and 15 percent of patients are resistant to Gleevec right away or within the first six months of treatment. AROG Pharmaceuticals may have an option for a few of those patients.

6 01, 2011

New Treatments of D842V Mutations

By |2019-04-03T12:02:19-04:00January 6th, 2011|Clinical Trials, D842V, Diagnosis, Mutational Testing, Mutations, News, Research|

 UPDATE - January 6th, 2011 by Jerry Call, LRG Science Coordinator The first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled [...]

20 12, 2007

References – PDGFRA and D842V

By |2019-08-26T14:48:37-04:00December 20th, 2007|D842V, Mutations, Research|

1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR: Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. [...]

18 09, 2020

New Horizons GIST 2020

By |2020-09-18T11:27:11-04:00September 18th, 2020|Advocacy, Global, News|

The New Horizons GIST 2020 Virtual Meeting kicked off on Thursday September 10th at 8am EST. Meeting since 2003, these patient advocates for various cancers split off to a GIST-only meeting several years ago. This year’s meeting, originally planned for Berlin, Germany, was held virtually September 10-12th.

30 06, 2020

Blueprint Medicines Announces Publication in The Lancet Oncology

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

15 05, 2020

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

By |2020-05-15T10:10:47-04:00May 15th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top